Anavex Life Sciences Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Anavex Life Sciences s intäkter har minskat med en genomsnittlig årlig takt på -5.5%, medan Biotechs -branschen såg intäkter på växer vid 37.6% årligen.
Viktig information
-5.48%
Tillväxttakt i vinsten
-0.18%
Tillväxttakt för EPS
| Biotechs Tillväxt i branschen | 17.04% |
| Intäkternas tillväxttakt | n/a |
| Avkastning på eget kapital | -31.55% |
| Nettomarginal | n/a |
| Senaste uppdateringen av resultatet | 31 Dec 2025 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Seeking Alpha • Jun 29
Anavex Life Sciences: Waiting On Validation As Blarcamesine Shows Some Promise
Summary Anavex Life Sciences is rated Hold, reflecting a strong balance sheet but high dependence on regulatory clarity for blarcamesine. AVXL's cash position of $131.7M supports a multi-year runway, with reduced operating expenses and minimal liabilities enhancing financial stability. Blarcamesine's Phase 2b/3 data showed statistically significant slowing of cognitive decline, but regulatory concerns over efficacy consistency and methodology persist. Valuation discounts pipeline optionality, with market cap near cash levels; upside hinges on confirmatory data and regulatory approvals. Read the full article on Seeking Alpha
Ny berättelse • Mar 05
Long-Term Neurology Pipeline And Precision Medicine Work Will Support A Stronger Outlook
Catalysts About Anavex Life Sciences Anavex Life Sciences is a clinical stage biopharmaceutical company focused on oral precision medicine therapies for neurological disorders such as early Alzheimer's disease, schizophrenia related conditions, Parkinson's disease, Fragile X syndrome and Rett syndrome. What are the underlying business or industry changes driving this perspective?Analysartikel • May 21
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 14
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Summary Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses. Given the EMA review's potential impact, I am considering a small investment, though not right now, acknowledging AVXL stock's high volatility and associated risks. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Summary Anavex Life Sciences' lead drug, Blarcamesine, failed to meet one of the two co-primary endpoints in its phase 2b/3 Alzheimer's trial, casting doubt on its efficacy and approval prospects. The trial's data inconsistencies, significant toxicity, and methodological flaws undermine the drug's potential for regulatory approval by the EMA. Despite a large market potential, the likelihood of approval is low, therefore we argue Anavex's fair valuation is cash basis ($1–$2 per share). Anavex's current financials show it is well-funded, but without successful trials, its future remains bleak. Read the full article on Seeking AlphaAnalysartikel • Dec 25
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Dec 24
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Summary Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes. Biogen and Lilly's approved amyloid-targeting drugs have limited efficacy and safety risks, highlighting the need for alternative Alzheimer's treatments like Anavex's approach. Unfortunately, I see too many red flags waving to endorse AVXL, but time will tell — the European approval shot is a major catalyst upcoming that I am bearish on. Read the full article on Seeking AlphaSeeking Alpha • Dec 08
Anavex: EU Approval Application Is A Precipitous Moment
Summary Anavex (AVXL) has submitted an MAA for blarcamesine in Alzheimer's, a critical step that puts their molecule under regulatory scrutiny. Despite past trial failures, Anavex's Phase 2b/3 trial showed significant cognitive improvements, though it failed one co-primary endpoint. Data inconsistencies and lack of US clinical trials raise concerns, but EU approval could still be possible. The EMA's decision on blarcamesine, expected by mid-2025, will be crucial, especially given the FDA's controversial approval of Biogen's Aduhelm. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Summary Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups. Safety profiles differ, with simufilam being safer but less effective long-term compared to blarcamesine. The latter may cause confusion and dizziness. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Summary On Thursday, Oct. 31, Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 conference. This news sent the stock soaring, with an ~16% increase in price. I take a look at the new data and share my thoughts here. Read the full article on Seeking AlphaSeeking Alpha • Oct 08
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Summary Anavex's lead drug, ANAVEX2-73, failed its Phase 2/3 trial for Rett syndrome, and Alzheimer's data showed questionable efficacy and concerning safety issues. The company's financial health is stable with a cash runway of about four years, but operational risks and rising costs are significant concerns. AVXL's decision to seek EU approval for ANAVEX2-73 based on limited data is perplexing, especially given the stringent regulatory environment. The overall recommendation is a "strong sell" due to poor clinical results, overvaluation, and high operational and financial risks. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Summary Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in the 50-mg arm, and 34.6% in the 30mg arm. On the negative side, the secondary endpoint was not met, and there was a seemingly high number of study withdrawals. Anavex wants to file for approval of Blarcamesine in Europe this year, and also with the FDA in the US. My suspicion is that the FDA will insist on further studies, and EMA may not be convinced on efficacy and safety. Read the full article on Seeking AlphaAnalysartikel • Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysartikel • Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysartikel • Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Anavex Life Sciences tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Dec 25 | 0 | -40 | 13 | 31 |
| 30 Sep 25 | 0 | -46 | 14 | 37 |
| 30 Jun 25 | 0 | -48 | 13 | 40 |
| 31 Mar 25 | 0 | -47 | 11 | 42 |
| 31 Dec 24 | 0 | -46 | 12 | 41 |
| 30 Sep 24 | 0 | -43 | 11 | 39 |
| 30 Jun 24 | 0 | -42 | 11 | 38 |
| 31 Mar 24 | 0 | -41 | 12 | 36 |
| 31 Dec 23 | 0 | -43 | 12 | 38 |
| 30 Sep 23 | 0 | -48 | 12 | 41 |
| 30 Jun 23 | 0 | -52 | 13 | 42 |
| 31 Mar 23 | 0 | -53 | 13 | 41 |
| 31 Dec 22 | 0 | -50 | 13 | 38 |
| 30 Sep 22 | 0 | -48 | 13 | 35 |
| 30 Jun 22 | 0 | -45 | 12 | 32 |
| 31 Mar 22 | 0 | -43 | 11 | 32 |
| 31 Dec 21 | 0 | -41 | 11 | 29 |
| 30 Sep 21 | 0 | -38 | 9 | 28 |
| 30 Jun 21 | 0 | -32 | 8 | 24 |
| 31 Mar 21 | 0 | -28 | 7 | 22 |
| 31 Dec 20 | 0 | -28 | 6 | 22 |
| 30 Sep 20 | 0 | -26 | 6 | 21 |
| 30 Jun 20 | 0 | -26 | 6 | 20 |
| 31 Mar 20 | 0 | -26 | 6 | 20 |
| 31 Dec 19 | 0 | -26 | 7 | 20 |
| 30 Sep 19 | 0 | -26 | 7 | 20 |
| 30 Jun 19 | 0 | -26 | 7 | 20 |
| 31 Mar 19 | 0 | -23 | 7 | 16 |
| 31 Dec 18 | 0 | -20 | 7 | 14 |
| 30 Sep 18 | 0 | -17 | 6 | 11 |
| 30 Jun 18 | 0 | -17 | 6 | 11 |
| 31 Mar 18 | 0 | -18 | 6 | 12 |
| 31 Dec 17 | 0 | -14 | 5 | 9 |
| 30 Sep 17 | 0 | -13 | 5 | 9 |
| 30 Jun 17 | 0 | -15 | 7 | 8 |
| 31 Mar 17 | 0 | -13 | 7 | 7 |
| 31 Dec 16 | 0 | -14 | 6 | 8 |
| 30 Sep 16 | 0 | -15 | 8 | 7 |
| 30 Jun 16 | 0 | -14 | 8 | 4 |
| 31 Mar 16 | 0 | -16 | 8 | 4 |
| 31 Dec 15 | 0 | -15 | 8 | 3 |
Kvalitetsintäkter: AVXL är för närvarande olönsam.
Växande vinstmarginal: AVXL är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: AVXL är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 5.5% per år.
Accelererande tillväxt: Det går inte att jämföra AVXL s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: AVXL är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 54.5% ).
Avkastning på eget kapital
Hög ROE: AVXL har en negativ avkastning på eget kapital ( -31.55% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/16 02:17 |
| Aktiekurs vid dagens slut | 2026/07/16 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/09/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Anavex Life Sciences Corp. bevakas av 9 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Jason Kolbert | D. Boral Capital LLC. |